WO2008028044A9 - Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel - Google Patents
Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel Download PDFInfo
- Publication number
- WO2008028044A9 WO2008028044A9 PCT/US2007/077247 US2007077247W WO2008028044A9 WO 2008028044 A9 WO2008028044 A9 WO 2008028044A9 US 2007077247 W US2007077247 W US 2007077247W WO 2008028044 A9 WO2008028044 A9 WO 2008028044A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- assessing
- markers
- methods
- ulcerative colitis
- related disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82398306P | 2006-08-30 | 2006-08-30 | |
| US60/823,983 | 2006-08-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008028044A2 WO2008028044A2 (en) | 2008-03-06 |
| WO2008028044A9 true WO2008028044A9 (en) | 2009-04-23 |
Family
ID=39136888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/077247 Ceased WO2008028044A2 (en) | 2006-08-30 | 2007-08-30 | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US7943310B2 (en) |
| WO (1) | WO2008028044A2 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2866726B1 (en) * | 2004-02-23 | 2006-05-26 | Jazzmutant | CONTROLLER BY HANDLING VIRTUAL OBJECTS ON A MULTI-CONTACT TOUCH SCREEN |
| US20080293582A1 (en) * | 2006-08-30 | 2008-11-27 | Xilin Li | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel |
| WO2008028044A2 (en) | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| EP2165194A4 (en) * | 2007-05-31 | 2010-09-08 | Abbott Lab | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNF-alpha INHIBITORS IN AUTOIMMUNE DISORDERS |
| WO2009117791A2 (en) | 2008-03-28 | 2009-10-01 | Katholieke Universiteit Leuven | Mucosal gene signatures |
| EP2326731B1 (en) * | 2008-08-25 | 2013-11-13 | Janssen Biotech, Inc. | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders |
| BRPI0917379A2 (en) * | 2008-08-29 | 2015-11-17 | Centocor Ortho Biotech Inc | markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel |
| NZ610075A (en) | 2010-11-08 | 2015-03-27 | Novartis Ag | Cxcr2 binding polypeptides |
| US20130218581A1 (en) * | 2011-04-26 | 2013-08-22 | Selventa, Inc. | Stratifying patient populations through characterization of disease-driving signaling |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| EP2716768A1 (en) * | 2012-10-04 | 2014-04-09 | IN. Medica, d.o.o. | Cell-based assay for assessing TNF alpha inhibitors |
| US10822406B2 (en) | 2015-01-29 | 2020-11-03 | Oxford University Innovation Limited | Method for treating chronic intestinal inflammation and inflammatory bowel disease by administering antagonists of Oncostatin-M (OSM) and/or antagonists of OSM receptor-beta (OSMR) |
| CN108290058B (en) | 2015-09-17 | 2023-05-16 | 美国安进公司 | Predicting clinical response of IL23 antagonists using IL23 pathway biomarkers |
| CA3116005A1 (en) * | 2018-10-19 | 2020-04-23 | Children's Hospital Medical Center | Use of mucosal transcriptomes for assessing severity of ulcerative colitis and responsiveness to treatment |
| EA202191354A1 (en) * | 2018-11-15 | 2021-08-11 | Янссен Байотек, Инк. | METHODS AND COMPOSITIONS FOR PREDICTION OF RESPONSE TO INFLAMMATORY INTESTINAL DISEASE THERAPY |
| EP3884276A2 (en) * | 2018-11-23 | 2021-09-29 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
| US11779643B2 (en) * | 2019-08-28 | 2023-10-10 | Children's Hospital Medical Center | Methods and compositions for the treatment of an inflammatory bowel disease |
| EP4305425A2 (en) * | 2021-03-12 | 2024-01-17 | Janssen Biotech, Inc. | Methods for predicting treatment response in ulcerative colitis |
| WO2025085674A1 (en) * | 2023-10-20 | 2025-04-24 | Bacainn Therapeutics, Inc. | Methods and compositions for the treatment of ulcerative colitis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| ATE205542T1 (en) | 1992-03-04 | 2001-09-15 | Univ California | COMPARATIVE GENOME HYBRIDIZATION |
| ATE424927T1 (en) | 1993-10-28 | 2009-03-15 | Houston Advanced Res Ct | MICROFABRICATED POROUS FLOW DEVICE FOR DISCRETE DETERMINATION OF BONDING REACTIONS |
| US20050123938A1 (en) * | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| AU2001255518A1 (en) | 2000-06-07 | 2001-12-17 | Baylor College Of Medicine | Compositions and methods for array-based nucleic acid hybridization |
| EP1545608A4 (en) | 2002-06-28 | 2006-09-13 | Centocor Inc | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
| US20060134663A1 (en) | 2004-11-03 | 2006-06-22 | Paul Harkin | Transcriptome microarray technology and methods of using the same |
| US20080293582A1 (en) * | 2006-08-30 | 2008-11-27 | Xilin Li | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel |
| WO2008028044A2 (en) | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| BRPI0917379A2 (en) | 2008-08-29 | 2015-11-17 | Centocor Ortho Biotech Inc | markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel |
-
2007
- 2007-08-30 WO PCT/US2007/077247 patent/WO2008028044A2/en not_active Ceased
- 2007-08-30 US US11/847,812 patent/US7943310B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090054253A1 (en) | 2009-02-26 |
| US7943310B2 (en) | 2011-05-17 |
| WO2008028044A2 (en) | 2008-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008028044A9 (en) | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel | |
| IL211154A0 (en) | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel | |
| AU2007208223A8 (en) | Methods and compositions for treating schizophrenia | |
| AU2006274834A8 (en) | Methods for preventing and treating metabolic disorders and new pyrazole-O-glycoside derivatives | |
| EP1977007A4 (en) | Markers and methods for assessing and treating psoriasis and related disorders | |
| EP1959929A4 (en) | Compositions and methods for treating dermatological conditions | |
| EP2052085A4 (en) | Methods for modulating set and uses thereof | |
| EP1987142A4 (en) | Esterases and related nucleic acids and methods | |
| TWI351224B (en) | Cursor controlling method and apparatus using the same | |
| TWI369545B (en) | Display panel and method for the same | |
| GB0603295D0 (en) | Methods and kits | |
| GB0716975D0 (en) | Computer apparatus and method of controlling the same | |
| WO2008137383A9 (en) | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel | |
| TWI349823B (en) | Electronic-ink display panel and the forming method thereof | |
| EP2100176A4 (en) | Substrates with slotted metals and related methods | |
| GB2437886B (en) | Method and equipment for the reduction of multiple dispersions | |
| ZA200806688B (en) | Methods of treating degenerative disorders with RAC 1B inhibitor | |
| ZA200807103B (en) | Investment and Loan Method and System | |
| PL2092081T3 (en) | Methods and uses involving genetic abnormalities at chromosome 12 | |
| GB0715201D0 (en) | Flavonoids-rich tissues from neomarica gracilis and methods for culturing the same | |
| HK1125413A (en) | Markers and methods for assessing and treating psoriasis and related disorders | |
| TWI349892B (en) | Chipset and control method thereof | |
| GB0503277D0 (en) | Computer-based teaching system | |
| HK1124236A (en) | Methods of treating degenerative disorders with rac 1b inhibitor | |
| TWI371739B (en) | Method for driving the lcd panel and lcd |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07814584 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07814584 Country of ref document: EP Kind code of ref document: A2 |